Neuroscience

Congress Materials – American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM 2025)

2025 American Association of Neuromuscular & Electrodiagnostic Medicine | Oct 29 - Nov 1 | San Francisco, CA

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Analysis of Long-Term Efficacy of Nipocalimab in Myasthenia Gravis: Open-Label Extension of the Vivacity-MG3 Trial

Nicholas J. Silvestri, Maria Ait-Tihyaty, Kavita Gandhi, Ibrahim Turkoz, Zia Choudhry, Wim Noel, Charlotte Gary, Sindhu Ramchandren

Congress Materials – American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM 2025)

Analysis of Long-Term Efficacy of Nipocalimab in Myasthenia Gravis: Open-Label Extension of the Vivacity-MG3 Trial

Composite Response To Nipocalimab Based On Both Myasthenia Gravis Activity Of Daily Living And Quantitative Myasthenia Gravis Scores In Patients With Generalized Myasthenia Gravis​

Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab (EPIC): Study design and Rationale

Efficacy of Nipocalimab in Adult Patients with Moderate-to-severe Ocular Manifestations of Generalized Myasthenia Gravis in Phase 3 Vivacity-MG3 Study

Efficacy of Nipocalimab in Open-Label Extension in Patients Transitioned from Placebo: Results from Vivacity-MG3 Trial

Factors Associated with Myasthenia Gravis – Activities of Daily Living Score in a Real-World, United States Population Prescribed Standard of Care Therapy

Impact of Generalized Myasthenia Gravis on Pregnancy Outcomes: Findings from a Healthcare Claims Database

Insights Into Nipocalimab-Neonatal Fragment Crystallizable Receptor Structure (FcRn), Binding Affinity, and Inhibition of Immunoglobulin G Recycling: Comparison With Efgartigimod

Nipocalimab in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Diagnostic Adjudication of the First 110 Patients of the Phase 2/3 ARISE Study

Patient and Caregiver Experiences of Symptom Instability and Unpredictability from a Myasthenia Gravis Patient Engagement Research Council: A Generative AI-Assisted Analysis

Predictors of Composite Response in Myasthenia Gravis Based on Patient and Clinician-Reported Assessments—In Vivacity-MG3 Phase 3 Trial

Refining the Conceptual Model of Patient Experiences in Chronic Inflammatory Demyelinating Polyneuropathy: Integrating New Data and Perspectives

Safety And Efficacy Results of Nipocalimab in Adolescents with Generalized Myasthenia Gravis During Active-Treatment and Long-term Extension Phases: VIBRANCE-MG Phase 2/3 Study

Safety Profile of Nipocalimab, a New Neonatal Fragment Crystallizable Receptor Blocker in the Phase 3 VIVACITY Study ​

Symptom Severity Assessment Using Quantitative Myasthenia Gravis Items and Domains in a 24-week, Phase 3 Study (Vivacity-MG3) of Nipocalimab in Generalized Myasthenia Gravis

Connect with us

Connect with us

Composite Response To Nipocalimab Based On Both Myasthenia Gravis Activity Of Daily Living And Quantitative Myasthenia Gravis Scores In Patients With Generalized Myasthenia Gravis

Safety Profile of Nipocalimab, a New Neonatal Fragment Crystallizable Receptor Blocker in the Phase 3 VIVACITY Study